Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Prostvac for Metastatic Castration Sensitive Prostate Cancer
NCT02649855Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2016
- Primary completion
- Jul 2022
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rilimogene galvacirepvec in prostate cancer (PCa) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Antigen Spreading (i.e., a Broader Immune Response) With Greater Associated Response Score at 19 weeks. Started Jan 2016; status: completed.
02
Drugs
rilimogene galvacirepvec
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02649855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02649855.